Physician profile
Derek Arthur Klemm
NPI 1225300494
$5,157.47
in general payments reported to CMS, 2019-2025
39 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 89% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $198 · 2021: $740 · 2022: $640 · 2023: $1,034 · 2024: $1,098 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.39 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $983.35 | 2021-2025 | |
| Corcept Therapeutics | $371.01 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $324.35 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $300.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $295.44 | 2021-2024 | |
| Alkermes, INC. | $280.70 | 2019-2025 | Vivitrol, Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.60 | 2019-2024 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals Lp | $255.86 | 2020-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $207.29 | 2023-2025 | Cologuard Collection Kit |
| Braeburn INC. | $185.42 | 2024-2025 | Brixadi |
| Daiichi Sankyo INC. | $180.22 | 2020-2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $167.52 | 2021-2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $164.84 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $121.75 | 2022-2025 | |
| Astellas Pharma US INC | $121.51 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $114.74 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $111.22 | 2021-2025 | Rexulti |
| Novo Nordisk INC | $105.74 | 2020-2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $47.73 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.04 | 2025 | Xifaxan |
| Abbott Laboratories | $41.65 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $41.48 | 2019-2021 | |
| Genentech USA, INC. | $38.79 | 2019-2021 | |
| Mylan Specialty L.P. | $38.40 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.20 | 2025 | Caplyta |
| Indivior INC. | $35.18 | 2024-2025 | Sublocade |
| Vertex Pharmaceuticals Incorporated | $35.00 | 2025 | |
| Amgen INC. | $33.65 | 2019-2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $31.78 | 2022-2023 | Ajovy |
| Allergan, INC. | $26.66 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.70 | 2023 | |
| Masimo Corporation | $20.65 | 2023 | Emma and Isa |
| Medtronic, INC. | $19.90 | 2024 | Minimed 780g |
| Lundbeck LLC | $18.08 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $15.83 | 2025 | Auvelity |
| Dexcom, INC. | $14.60 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $13.84 | 2024 | Unithroid |
| Janssen Pharmaceuticals, INC | $13.66 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Klemm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.